INOVIO Announces Financial Results for Q3 2025 and Key Developments

November 10, 2025 - 22:15

INOVIO has successfully completed the rolling submission of its Biologics License Application (BLA) for its lead candidate, INO-3107, aiming for accelerated approval. The company has also requested priority review from regulatory authorities, which could expedite the assessment of this promising therapeutic option.

During the third quarter of 2025, INOVIO reported significant advancements in its clinical programs and financial performance. The company is focused on developing innovative DNA medicines to address unmet medical needs, particularly in oncology and infectious diseases. The recent progress with INO-3107 highlights INOVIO's commitment to bringing novel therapies to market efficiently.

In addition to the BLA submission, INOVIO has been actively engaging with stakeholders and investors to communicate its strategic vision and growth plans. The ongoing development of INO-3107 and other pipeline candidates reflects the company's dedication to improving patient outcomes through cutting-edge science and technology. As the company moves forward, it anticipates further milestones that could enhance its position in the biopharmaceutical industry.